Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company

Eli Lilly's oral GLP-1, orforglipron, delivered strong results in its first pivotal Phase 3 trial (ATTAIN-1) for obesity, showing participants on the highest dose achieved an average weight loss of 27.3 lbs (12.4%) at 72 weeks, alongside improvements in cardiovascular risk factors. The safety profile was consistent with injectable GLP-1s, with generally mild-to-moderate gastrointestinal side effects. These positive outcomes position Lilly to submit orforglipron for regulatory approval by year-end, indicating a significant potential oral entrant in the rapidly growing GLP-1 obesity market.

Analysis

Eli Lilly's oral GLP-1 candidate, orforglipron, has demonstrated significant clinical efficacy in its first pivotal Phase 3 trial, ATTAIN-1, reinforcing the company's strategic position in the high-growth obesity market. The trial successfully met its primary endpoint, with the highest dose yielding a mean body weight reduction of 12.4% (27.3 lbs) at 72 weeks, substantially outperforming the 0.9% reduction seen with placebo. The results are further strengthened by meeting all key secondary endpoints, where 59.6% of participants on the highest dose achieved at least 10% weight loss. Importantly, the drug also showed improvements in cardiovascular risk markers, including a 47.7% reduction in hsCRP, which could enhance its value proposition. The safety profile was noted as consistent with the established GLP-1 class, characterized by mainly mild-to-moderate gastrointestinal adverse events. However, the dose-dependent treatment discontinuation rate due to these events, which reached 10.3% for the 36 mg dose compared to 2.6% for placebo, is a key consideration for real-world patient adherence. The company's stated plan for regulatory submissions by year-end and its proactive investment in manufacturing capacity signal strong commercial conviction ahead of a potential launch.

Key Decisions for Investors

• The positive Phase 3 data significantly de-risks orforglipron's clinical pathway and solidifies Eli Lilly's growth pipeline in the lucrative obesity market, presenting a strong rationale for maintaining or increasing long positions.
• Monitor upcoming catalysts closely, specifically the planned regulatory submissions by year-end and further data from the ATTAIN and ACHIEVE trial programs, as these will be critical drivers for the stock's performance.
• Investors should weigh the compelling efficacy against the 10.3% discontinuation rate due to side effects at the highest dose, as this metric will be crucial for modeling real-world market share and competitive positioning against other GLP-1 therapies.